Late-Onset Neutropenia after Rituximab Treatment for Adult-Onset Nephrotic Syndrome

• Published in: Case Reports in Nephrology Vol. 2019; no. 2019; pp. 1 - 4
• Main Authors: Tsuchiya, Ken, Amemiya, Nobuyuki, Nokiba, Hirohiko, Kyoda, Mizuki, Iwatani, Yosuke, Sugiura, Hidekazu, Yamazaki, Mayuko, Nitta, Kosaku
• Format: Journal Article
• Language: English
• Published: Cairo, Egypt Hindawi Publishing Corporation 2019; Hindawi; John Wiley & Sons, Inc; Hindawi Limited; Wiley
• Subjects: Abdomen; Arthritis; Autoimmune diseases; B cells; Biopsy; Blood; Case Report; Case reports; Cytotoxicity; Drug dosages; Drug therapy; Edema; Health risk assessment; Hematology; Hepatitis; Immunotherapy; Kidney diseases; Lupus; Lymphoma; Monoclonal antibodies; Nephrotic syndrome; Neutropenia; Neutrophils; Non-Hodgkin's lymphomas; Rheumatoid arthritis; Rheumatoid factor; Targeted cancer therapy; Transplantation of organs, tissues, etc; Transplants & implants; Japan
• ISSN: 2090-6641; 2090-665X
• DOI: 10.1155/2019/3580941

A 41-year-old woman developed nephrotic syndrome at the age of 32 and was diagnosed with minimal change nephrotic syndrome based on a renal biopsy. Although remission was achieved with administration of prednisolone (PSL) and cyclosporine, the nephrotic syndrome recurred. She was also started on rituximab (RTX). She developed late-onset neutropenia after RTX treatment (R-LON) and improved 17 days later. Although the majority of R-LON cases undergo spontaneous remission, cases of death have been reported. This report is intended to warn about R-LON, since the use of RTX for adult-onset nephrotic syndrome is expected to increase in the future.